Effects of fexofenadine, diphenhydramine, and placebo on performance of the Test of Variables of Attention (TOVA)

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 5, 2003, Pages 554-559

  Mansfield, Lyndon ^a   Mendoza, Catherine ^a   Flores, Jaime ^a   Meeves, Suzanne G ^b  

^a El Paso Institute of Medical Research and Development   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; FEXOFENADINE; PLACEBO; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; MALE; MEASUREMENT; NORMAL HUMAN; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SELF REPORT; STATISTICAL SIGNIFICANCE; TEST OF VARIABLES OF ATTENTION; VISUAL ANALOG SCALE; ATTENTION; COMPARATIVE STUDY; MIDDLE AGED; REACTION TIME; SLEEP STAGE;

ADOLESCENT; ADULT; ATTENTION; COGNITION; CROSS-OVER STUDIES; DIPHENHYDRAMINE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; REACTION TIME; SLEEP STAGES; TERFENADINE;

EID: 0037531124     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61850-9     Document Type: Article

References (23)

1. Nolen TM. Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin Ther. 1997;19:39-55.
2. Hindmarch I, Shamsi Z. Antihistamines: models to assess the sedative properties, assessment of sedation, safety and other side effects. Clin Exp Allergy. 1999;29(Suppl):133-142.
3. Schatz AM, Ballantyne AO, Trauner DA. Sensitivity and specificity of a computerized test of attention in the diagnosis of attention-deficit/hyperactivity disorder. Assessment. 2001;8:357-365.
4. Forbes GB. Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder. J Clin Psychol. 1998;54:461-476.
5. Leark RA, Dupuy TR, Greenberg LM, Corman CK, Kindshi C. T. O. V. A. Test of Variables of Attention: Professional Guide. Los Alamitos, CA: Universal Attention Disorders, 1999.
6. Greenberg LM, Waldman ID. Developmental normative data on the test of variables of attention (T.O.V.A.). J Child Psychol Psychiatry. 1993;34:1019-1030.
7. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry. 2001;40;230-235.
8. Lubar JF, White JN, Swartwood MO, Swartwood JN. Methylphenidate effects on global and complex measures of EEG. Paediatr Neurol. 1999;21:633-637.
9. Bernstein GA, Carroll ME, Crosby RD, Perwien AR, Go FS, Benowitz NL. Caffeine effects on learning, performance, and anxiety in normal school-age children. J Am Acad Child Psychiatry. 1994;33:407-415.
10. Downey KK, Stelson FW, Pomerleau OF, Giordani B. Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. J Nerv Ment Dis. 1997;185:32-38.
11. Wada N, Yamashita Y, Matsuishi T, Ohatani Y, Kato H. The test of variables of attention (TOVA) is useful in the diagnosis of Japanese male children with attention deficit hyperactivity disorder. Brian Dev. 2000;22:378-382.
12. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol. 1994;94:716-724.
13. Dupuy TR, Greenberg LM. TOVA Manual. Greenberg LM, editor. Los Alamitos, CA: Universal Attention Disorders, 1993.
14. Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med. 2000;132:354-363.
15. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Asthma Allergy Immunol. 2000;85:338-348.
16. Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J. Effect of fexofenadine HCI on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis Am J Manag Care. 1999;5(Suppl):S235-S247.
17. 1 receptor antagonist, fexofenadine. Int Arch Allergy Immunol. 1999;118:338.
18. 1-antihistamine, cetirizine. Aviat Space Environ Med. 1998;69:166-171.
19. Vermeeren A, O'Hanlon JF. Fexofenadine effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol. 1998;101:306-311.
20. Clarinex [package insert]. Kenilworth, NJ: Schering Corporation; 2002.
21. Zyrtec [package insert]. New York, NY: Pfizer; 2002.
22. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(Suppl):163-170.
23. Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83:311-317.